Bli medlem
Bli medlem

Du är här


Vicore Pharma: Selektope® wins European Marine Engineering Award


Vicore Pharma Holdings financial asset, I-Tech recently won a prestigious
prize arranged by the European Marine Engineering awards for their
antifouling substance, Selektope®. Read more about the award below!

Gothenburg-based I-Tech's Selektope® antifouling agent has secured one of
the prestigious European Marine Engineering Awards 2016, in recognition of
the breakthrough marine coating ingredient's Environmental Performance.

The Environmental Performance Award, sponsored by DNV GL, celebrates the
environmental benefits of a product, process or management approach as a
result of implementation for the first time in 2015, or significantly
improved or relaunched,

The Award was presented by Robert Ashdown, Secretary General of the
International Association of Classification Societies at the European
Marine Engineering Conference gala dinner in Amsterdam on 13th April 2016.
I-Tech Chief Executive Philip Chaabane said: "It is a great honour for the
environmental performance of Selektope to be recognized by an Award that
takes into account the views of an independent panel of European Marine
engineering judges and a public vote. This is a fantastic accolade,
celebrating our ten-year-plus journey from scientific breakthrough to
Selektope as a fully approved and available, anti-fouling agent that acts
as a repellant to barnacles attaching themselves to ship hulls."

Selektope is an organic, non-metal compound, which features an innovative
pharmacological mode of action to combat barnacle settlement, even in
minute quantities. It temporarily stimulates the swimming action in
barnacle larvae's, deterring them from attaching to the hull. It is
distinguished by extremely low biocidal loading and is harmless to the
marine environment.

Initial commercial applications of marine coatings with Selektope, which is
now fully approved for use by the relevant authorities in Japan, South
Korea, China and Europe, took place in 2015. Following paint product
launches in the Japanese market and the Korean new build market, both in
2015), Selektope is now a high volume product. Its first
publically-disclosed application took place at Sembcorp in Singapore, when
a new copper-free product from Chugoku Marine Paints (CMP) was applied to
the side walls of the 2010-built, 46,000dwt chemical carrier Calypso
operated by Sweden's Laurin Maritime.

Tests have shown that antifouling products containing Selektope also
significantly reduce fouling, lowering water resistance and potentially
saving up to 40% in fuel costs, and thereby cutting ship air emissions.
Selektope repels barnacles even when ships are at rest, allowing fuel
saving claims made by coatings suppliers to cover the ship's entire
operational cycle.

By repelling barnacle attachment, coatings with Selektope also lower the
risk of transporting invasive aquatic species from one oceanic region to

The European Marine Engineering Awards are organised by Riviera Maritime
Media. Award winners are selected after a dual process, reflecting
consideration by a panel of independent judging experts from various marine
engineering disciplines but also a public vote.

Selektope® - further improving antifouling paints
Selektope introduces for the first time ever a pharmacological mode of
action to combat barnacle settlement. By temporarily stimulating the
octopamine receptor, the barnacle larvae's swimming behaviour is activated
and the organisms are deterred from the hull. These ground-breaking
discoveries enable unrivalled power at very low concentrations, yet within
the limits of rigorous risk assessments. Selektope is an organic, non-metal
compound with efficacy proven at 0.1% w/w.

About I-Tech
I-Tech is a Gothenburg based bio-tech company with global reach, holding
all IP and regulatory rights to its all new antifouling agent Selektope
(generic name, medetomidine).

The company is privately held and is supported by Swedish Energy
Association, the European Innovation Initiative Eco-Innovation and FP7
SeaFront. The company is a member of the Astra Zeneca BioVentureHub.



Contact details Vicore Pharma Holding
Nina Carlén, Communications,
+46 (0)763 90 94 04

The following documents can be retrieved from beQuoted
Vicore Pharma Pressrelease 2016-04-15.pdf

Vicore Pharmas aktier är noterade på NASDAQ Stockholm, First North, och
handlas under kortnamnet VICO. Bolagets Certified Adviser är Redeye AB.

Författare BEQ

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.